2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - La Nouvelle C
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Biological Processes, CHIP, Clinical Practice (Health Services and Quality), Value, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult
PAPER

942 The cheerleader effect: Surrogate endpoint accumulation and interpretation of benefit in randomized myeloma trials

Muftah Mahmud, MD, Jugraj Singh, MD2, Mahmood Numan, MD3
1 University of Arizona College of Medicine, Tucson, Arizona, United States
2 Midwestern University Internal Medicine Residency Consortium, Verde Valley Medical Center, Cottonwood, Arizona, United States
3 University of Arizona College of Medicine, Tucson, Arizona, United States

Background: Randomized controlled trials (RCTs) in multiple myeloma (MM) often report several positive surrogate endpoints, including overall response rate (ORR), depth of response, minimal residual disease (MRD) negativity, and progression-free survival (PFS). Although these endpoints provide important evidence of treatment activity, reporting multiple favorable surrogate outcomes together may lead to a more favorable interpretation of treatment benefit than is ultimately supported by overall survival (OS). We refer to this phenomenon as the Cheerleader Effect and examined its presence across pivotal randomized MM trials.

Methods: We performed a systematic review of pivotal phase II and III randomized controlled trials evaluating therapies for newly diagnosed and relapsed/refractory MM. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed/MEDLINE, Embase, Cochrane CENTRAL, and ClinicalTrials.gov were searched for eligible trials published between January 1, 2015, and June 30, 2026. Two investigators independently screened studies for eligibility, with disagreements resolved by consensus. For each eligible trial, four surrogate efficacy domains were assessed: overall response rate (ORR), depth of response (≥VGPR or complete response), minimal residual disease (MRD) negativity, and progression-free survival (PFS). Each statistically significant surrogate endpoint contributed one point to a surrogate positivity score (range, 0–4). Mature OS outcomes were categorized as significant benefit, favorable but statistically non-significant trend, neutral, or harm signal. Treatment class, crossover, and reporting of quality-of-life (QoL) or patient-reported outcomes (PROs) were also recorded. Concordance between surrogate positivity and mature OS outcomes was evaluated descriptively, with Spearman rank correlation and the Cochran-Armitage trend test performed as exploratory analyses.

Results: Twenty-four pivotal RCTs met the inclusion criteria, including 19 conventional systemic therapy trials and 5 cellular or bispecific immunotherapy trials. Five trials (20.8%) permitted crossover, and 21 (87.5%) reported QoL or PROs. Because OS follow-up remained immature for GRIFFIN, PERSEUS, and MagnetisMM-5, these studies were excluded from the concordance analysis, leaving 21 evaluable trials.

Surrogate positivity scores were high overall: 9 trials (42.9%) scored 4, 6 (28.6%) scored 3, 4 (19.0%) scored 2, and 2 (9.5%) scored 1. Most trials with the maximum surrogate positivity score demonstrated a significant OS benefit (7/9, 77.8%); however, two did not, including one with an OS harm signal. The relationship was less consistent among trials with a surrogate positivity score of 3, where only two of six demonstrated a significant OS benefit, while the remaining trials showed either favorable but statistically non-significant trends or neutral survival outcomes. Higher surrogate positivity scores generally aligned with better OS outcomes, although the trend did not reach statistical significance (Spearman ρ = 0.40, P = 0.07; Cochran-Armitage trend test P = 0.22). Importantly, several trials with uniformly positive surrogate endpoints did not demonstrate a clear survival benefit.

Limitations: This analysis was based on published trial-level data rather than individual patient data and used an unweighted surrogate scoring system. Differences in trial design, patient populations, crossover, duration of follow-up, and subsequent therapies may also have influenced OS outcomes.

Conclusions: Overall, trials with greater surrogate endpoint positivity tended to be associated with improved overall survival, although this association did not reach statistical significance (Spearman ρ = 0.40, P = 0.07) and was marked by notable exceptions. Notably, two of the nine trials with the highest surrogate positivity scores failed to improve OS, including one that demonstrated an OS harm signal. We describe this pattern as the Cheerleader Effect—the tendency for multiple positive surrogate endpoints to reinforce confidence in a treatment even when mature survival data are less convincing. These findings emphasize the importance of interpreting surrogate endpoints alongside overall survival rather than in isolation and provide a foundation for future studies of surrogate endpoint interpretation in multiple myeloma trials.
Muftah Mahmud, MD: No relevant conflicts of interest to declare.